WallStreetZenWallStreetZen

NASDAQ: DNTH
Dianthus Therapeutics Inc Stock

$25.43-2.07 (-7.53%)
Updated Oct 14, 2024
DNTH Price
$25.43
Fair Value Price
$19.13
Market Cap
$746.48M
52 Week Low
$6.58
52 Week High
$33.77
P/E
6.17x
P/B
2.08x
P/S
215.1x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.12M
Earnings
-$56.68M
Gross Margin
100%
Operating Margin
-1,376.42%
Profit Margin
-1,376.4%
Debt to Equity
0.03
Operating Cash Flow
-$24M
Beta
1.11
Next Earnings
Nov 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

DNTH Overview

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DNTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

DNTH ($25.43) is overvalued by 32.92% relative to our estimate of its Fair Value price of $19.13 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DNTH ($25.43) is not significantly undervalued (32.92%) relative to our estimate of its Fair Value price of $19.13 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DNTH is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more DNTH due diligence checks available for Premium users.

Be the first to know about important DNTH news, forecast changes, insider trades & much more!

DNTH News

Valuation

DNTH fair value

Fair Value of DNTH stock based on Discounted Cash Flow (DCF)
Price
$25.43
Fair Value
$19.13
Overvalued by
32.92%
DNTH ($25.43) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DNTH ($25.43) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

DNTH price to earnings (PE)

For valuing profitable companies with steady earnings
Company
6.17x
Industry
-124.07x
Market
27.44x
DNTH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DNTH is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

DNTH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.08x
Industry
6.12x
DNTH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

DNTH's financial health

Profit margin

Revenue
$1.9M
Net Income
-$17.6M
Profit Margin
-945.1%
DNTH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DNTH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$369.0M
Liabilities
$10.7M
Debt to equity
0.03
DNTH's short-term assets ($365.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DNTH's short-term assets ($365.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DNTH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DNTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$14.5M
Investing
$1.2M
Financing
-$2.2M
DNTH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

DNTH vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
DNTH$746.48M-7.53%6.17x2.08x
ABCL$742.56M-2.70%-4.67x0.67x
TNGX$732.87M-0.29%-6.11x2.96x
ADPT$729.99M+0.20%-3.37x3.02x
IMNM$729.66M-0.65%-1.58x2.87x

Dianthus Therapeutics Stock FAQ

What is Dianthus Therapeutics's quote symbol?

(NASDAQ: DNTH) Dianthus Therapeutics trades on the NASDAQ under the ticker symbol DNTH. Dianthus Therapeutics stock quotes can also be displayed as NASDAQ: DNTH.

If you're new to stock investing, here's how to buy Dianthus Therapeutics stock.

What is the 52 week high and low for Dianthus Therapeutics (NASDAQ: DNTH)?

(NASDAQ: DNTH) Dianthus Therapeutics's 52-week high was $33.77, and its 52-week low was $6.58. It is currently -24.7% from its 52-week high and 286.47% from its 52-week low.

How much is Dianthus Therapeutics stock worth today?

(NASDAQ: DNTH) Dianthus Therapeutics currently has 29,354,320 outstanding shares. With Dianthus Therapeutics stock trading at $25.43 per share, the total value of Dianthus Therapeutics stock (market capitalization) is $746.48M.

Dianthus Therapeutics stock was originally listed at a price of $232.32 in Jun 21, 2018. If you had invested in Dianthus Therapeutics stock at $232.32, your return over the last 6 years would have been -89.05%, for an annualized return of -30.84% (not including any dividends or dividend reinvestments).

How much is Dianthus Therapeutics's stock price per share?

(NASDAQ: DNTH) Dianthus Therapeutics stock price per share is $25.43 today (as of Oct 14, 2024).

What is Dianthus Therapeutics's Market Cap?

(NASDAQ: DNTH) Dianthus Therapeutics's market cap is $746.48M, as of Oct 15, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Dianthus Therapeutics's market cap is calculated by multiplying DNTH's current stock price of $25.43 by DNTH's total outstanding shares of 29,354,320.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.